Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Dow Jones Futures: Fed Hike Due, PacWest, AMD In Focus. Eli Lilly Drug Slows Alzheimer's.

Another rate hike is expected today, but Fed guidance will be key. PacWest rebounded while AMD tumbled. Eli Lilly jumped on its Alzheimer's drug.

Investors Business Daily

Eli Lilly Surges On Promising Data From Late-Stage Alzheimer's Drug Trial

"This is the first Phase 3 trial of any investigational medicine for Alzheimer's disease to deliver 35% slowing of clinical and functional decline," Eli Lilly said.

The Street

Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?

Industry analysts warn that a groundbreaking change in how Medicare buys drugs threatens industry growth, profits — and maybe patient care.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

New weight loss drug helping people lose 2.5 stone is 'coming to the UK'

A weekly injection of tirzepatide has seen people with obesity and diabetes lose over 15 percent of their bodyweight.

Daily Record

Weight loss jab that can help patients shed two-and-a-half stone set for UK approval

Tirzepatide could be given to patients with diabetes or heat disease

The Independent UK

Markets Today: Stock Index Futures Climb on Meta’s Earnings

Morning Markets June E-Mini S&P 500 futures (ESM2 3) this morning are up +0.47%, and June Nasdaq 100 E-Mini futures (NQM2 3) are up +0.87%. U.S. stock index futures this morning are moderately higher. Strength in technology stocks is lifting the overall market this morning, with Meta Platforms up more...

Barchart

Eli Lilly Unveils New Obesity Data As Mounjaro Blows Past Sales Estimates

Eli Lilly stock surged Thursday after diabetes drug Mounjaro blew past sales projections and led to promising weight loss in a Phase 3 study.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly releases more data for new obesity drug, moving toward fast-track approval

There's already a huge demand for existing weight-loss drugs, so the new medication is highly anticipated. Obesity affects an estimated 650 million adults globally.

WEKU

Dow Jones Futures Rise: Meta Soars, Drug Giants Climb, Specialty Chip Plays Dive

Futures: Meta Platforms boomed on earnings, but megacap techs can't hide broad market rally weakness. First Republic dived again.

Investors Business Daily

Novo Nordisk Sinks As Eli Lilly Plots Its Showdown In Obesity

Novo Nordisk stock dipped Monday after Eli Lilly posted the details of its study comparing Mounjaro and Wegovy in obesity treatment.

Investors Business Daily

Jim Cramer Bluntly Schools Stock-Buyers On 3 'Amazing American' Companies

The CNBC host offers some pointed thoughts.

The Street

Manager Of Top T. Rowe Price Fund Is Still 'Pretty Cautious'

Looking for a go-anywhere stock fund that isn't trapped in a style box and can buy stocks of all sizes and styles? Well, Justin White's T. Rowe Price All-Cap Opportunities Fund checks all those boxes.

Investors Business Daily

Eli Lilly Stock Shows Improved Relative Strength; Still Shy Of Benchmark

A Relative Strength Rating upgrade for Eli Lilly shows improving technical performance. Will it continue?

Investors Business Daily

Australian news publishers palm off payment for Twitter Blue verification

Publishers appear unlikely to pay for verification after the platform warned legacy accounts would be stripped of checkmarks from April 1.

Crikey

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Novo Hits Another Record High As WHO Considers A Key Move In Obesity

The World Health Organization will consider adding obesity treatments to its "essential medicines list." The move could help some drug stocks.

Investors Business Daily

Novartis Surges As It Goes After Eli Lilly's Second Biggest Moneymaker

Novartis stock surged Monday after the company's treatment reduced the risk of relapse in patients with early-stage breast cancer.

The Guardian - UK

‘I skip meals to make my insulin last’: the cost of diabetes in the global south

The three firms that control the insulin market are to cut costs in the US, but elsewhere users can spend all their pay to get the life-saving drug

AFP

Sanofi, joining other drug makers, slashes US insulin price

New York (AFP) - French pharmaceutical giant Sanofi announced on Thursday it would cut the US price of its most prescribed insulin by 78 percent, falling in line with two other major drug makers.

Get all your
news in one place.

100’s of premium titles.
One news app.

Axios

The biggest U.S. pharmaceutical companies are lowering insulin costs to save themselves money

So much for altruism.

Chicago Sun-Times

Anti-obesity drug demand expected to skyrocket, but will insurance cover the cost?

New weight loss drugs can cost more than $1,000 a month, but most health plans don’t cover them.

Investors Business Daily

Eli Lilly Stock Shows Improved Relative Price Performance; Still Shy Of Benchmark

A Relative Strength Rating upgrade for Eli Lilly shows improving technical performance. Will it continue?

WEKU

Novo Nordisk will cut some U.S. insulin prices by up to 75% starting next year

The Danish drugmaker's move follows a similar announcement by rival Eli Lilly earlier this month. More than 8 million Americans use insulin, according to the American Diabetes Association.

Inverse

This Essential Medical Treatment Could Finally Become Affordable For Everyone

Pharmaceutical giant Eli Lilly is slashing the list prices for some of its most popular insulin products by 70 percent.

Investors Business Daily

Eli Lilly's Decade-Long Effort In Alzheimer's Disease Just Failed

Eli Lilly stock and Biogen stock diverged Thursday after Lilly said a decade-long study of an Alzheimer's treatment definitively failed.

Miami Herald

$35 for insulin? What to know about Eli Lilly’s price slash for the diabetic medicine

Eli Lilly plans to slash the cost of some of its most popular insulin drugs later this year for people with and without insurance, in a move that could make the lifesaving medication more affordable for some patients living with diabetes.

1 … 18 19 20 21

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations